LGL Partners LLC Acquires 100 Shares of Novo Nordisk A/S (NYSE:NVO)

LGL Partners LLC increased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 2.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,216 shares of the company’s stock after buying an additional 100 shares during the period. LGL Partners LLC’s holdings in Novo Nordisk A/S were worth $540,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of NVO. Pacific Center for Financial Services boosted its holdings in shares of Novo Nordisk A/S by 100.0% in the third quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after buying an additional 135 shares during the period. Copeland Capital Management LLC grew its stake in Novo Nordisk A/S by 100.0% during the third quarter. Copeland Capital Management LLC now owns 282 shares of the company’s stock worth $26,000 after buying an additional 141 shares in the last quarter. Bell Investment Advisors Inc grew its stake in Novo Nordisk A/S by 79.9% during the third quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock worth $26,000 after buying an additional 127 shares in the last quarter. CNB Bank acquired a new stake in Novo Nordisk A/S during the fourth quarter worth about $26,000. Finally, Citizens National Bank Trust Department grew its stake in Novo Nordisk A/S by 100.0% during the third quarter. Citizens National Bank Trust Department now owns 300 shares of the company’s stock worth $27,000 after buying an additional 150 shares in the last quarter. 11.54% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. BMO Capital Markets started coverage on shares of Novo Nordisk A/S in a research note on Friday, April 12th. They set an “outperform” rating and a $163.00 price objective on the stock. UBS Group started coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 16th. They issued a “neutral” rating for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Thursday, April 18th. Finally, Morgan Stanley began coverage on Novo Nordisk A/S in a research note on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 target price on the stock. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $133.60.

Novo Nordisk A/S Price Performance

Shares of NVO traded up $1.42 during midday trading on Tuesday, hitting $128.30. 6,373,105 shares of the company traded hands, compared to its average volume of 4,782,995. Novo Nordisk A/S has a one year low of $75.56 and a one year high of $138.28. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.82 and a quick ratio of 0.64. The firm has a market cap of $575.75 billion, a P/E ratio of 47.77, a PEG ratio of 2.12 and a beta of 0.41. The stock has a 50-day moving average of $126.92 and a 200-day moving average of $112.40.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, January 31st. The company reported $0.71 earnings per share for the quarter, beating analysts’ consensus estimates of $0.66 by $0.05. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. The firm had revenue of $9.51 billion for the quarter, compared to analysts’ expectations of $9.14 billion. As a group, sell-side analysts predict that Novo Nordisk A/S will post 3.32 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently disclosed a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Stockholders of record on Monday, March 25th were issued a dividend of $0.664 per share. This represents a dividend yield of 0.9%. This is a boost from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. The ex-dividend date of this dividend was Friday, March 22nd. Novo Nordisk A/S’s dividend payout ratio is 49.17%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.